New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a ...

A pioneering heart centre at Basildon Hospital is celebrating a major milestone after carrying out its 1,000th "life-changing procedure". The Essex Cardiothoracic Centre (CTC), based at Basildon ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms.

Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients ...

Edwards Lifesciences announced the FDA approved its transcatheter aortic valve replacement platform for treatment of severe ...

FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis ...

The agency’s decision for the balloon-expandable Sapien 3 platform is based on groundbreaking results from EARLY TAVR.

Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure used to replace damaged heart valves, ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic stenosis (AS), a valvular heart condition that can be ...

Compared with usual care, a system of electronic provider notification more often enabled patients diagnosed with severe ...

Hypothesis: Higher LVEDWS to LVESWS ratio assessed by echocardiography prior to TAVR associates ... Conclusion: Among patients with severe aortic stenosis, higher LVEDWS to LVESWS ratio prior to TAVR ...